OLD Second National Bank of Aurora Lowers Stake in Allergan plc (AGN)
OLD Second National Bank of Aurora cut its holdings in shares of Allergan plc (NYSE:AGN) by 78.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,134 shares of the company’s stock after selling 4,238 shares during the period. OLD Second National Bank of Aurora’s holdings in Allergan were worth $186,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Pathstone Family Office LLC grew its position in shares of Allergan by 3,327.3% during the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock worth $2,035,000 after acquiring an additional 366 shares during the last quarter. Howard Hughes Medical Institute purchased a new position in shares of Allergan during the second quarter worth approximately $103,000. Massey Quick & Co. LLC grew its position in shares of Allergan by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after acquiring an additional 385 shares during the last quarter. Cable Hill Partners LLC grew its position in shares of Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after acquiring an additional 370 shares during the last quarter. Finally, Pacific Center for Financial Services grew its position in shares of Allergan by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after acquiring an additional 7 shares during the last quarter. Institutional investors and hedge funds own 81.26% of the company’s stock.
AGN has been the topic of a number of research reports. Cowen restated a “buy” rating on shares of Allergan in a research report on Thursday, October 12th. UBS Group reiterated a “buy” rating and issued a $275.00 price objective on shares of Allergan in a research report on Tuesday, September 26th. Wells Fargo & Co reiterated a “buy” rating on shares of Allergan in a research report on Monday, October 2nd. Mizuho reiterated a “buy” rating and issued a $267.00 price objective on shares of Allergan in a research report on Monday, September 25th. Finally, Citigroup reiterated a “buy” rating and issued a $280.00 price objective on shares of Allergan in a research report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. Allergan presently has an average rating of “Hold” and an average price target of $226.95.
Allergan plc (AGN) traded down $1.94 during trading on Wednesday, reaching $176.72. The company’s stock had a trading volume of 2,198,457 shares, compared to its average volume of 2,539,890. Allergan plc has a 12 month low of $160.07 and a 12 month high of $256.80. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $59,420.00, a P/E ratio of -7.82, a P/E/G ratio of 1.30 and a beta of 1.11.
Allergan (NYSE:AGN) last released its earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating analysts’ consensus estimates of $4.06 by $0.09. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter last year, the company earned $3.32 earnings per share. Allergan’s quarterly revenue was up 11.4% compared to the same quarter last year. equities analysts anticipate that Allergan plc will post 16.27 EPS for the current fiscal year.
Allergan declared that its board has initiated a stock repurchase program on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its stock is undervalued.
In other Allergan news, Director Chris W. Bodine bought 3,030 shares of Allergan stock in a transaction on Thursday, December 7th. The stock was bought at an average price of $164.77 per share, with a total value of $499,253.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Meury sold 11,807 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. In the last three months, insiders acquired 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.dailypolitical.com/2018/01/17/old-second-national-bank-of-aurora-lowers-stake-in-allergan-plc-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.